These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2600782)

  • 1. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
    Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
    J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
    Chakraborty BS; Hawes EM; McKay G; Hubbard JW; Korchinski ED; Midha KK; Choc MG; Robinson WT
    Drug Metabol Drug Interact; 1988; 6(3-4):425-37. PubMed ID: 3271648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
    Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
    Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
    Salih IS; Thanacoody RH; McKay GA; Thomas SH
    Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.
    Lin G; Hawes EM; McKay G; Korchinski ED; Midha KK
    Xenobiotica; 1993 Oct; 23(10):1059-74. PubMed ID: 8259689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a radioimmunoassay procedure for mesoridazine and its comparison with a high-performance liquid chromatographic method.
    Chakraborty BS; Hawes EM; Midha KK
    Ther Drug Monit; 1987 Dec; 9(4):464-71. PubMed ID: 3424415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
    Niedzwiecki DM; Mailman RB; Cubeddu LX
    J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption and excretion of thioridazine and mesoridazine in man.
    Charalampous KD; Johnson PC; Estevez V
    Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
    Rao ML; Brown WA; Wagner R
    Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
    Eap CB; Souche A; Koeb L; Baumann P
    Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
    Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a metabolite of thioridazine and mesoridazine from human plasma.
    Gruenke LD; Craig JC
    Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):221-5. PubMed ID: 1162173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
    Daniel WA; Syrek M; Haduch A; Wójcikowski J
    Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a radioimmunoassay procedure for sulforidazine and its comparison with a high-performance liquid chromatographic method.
    Chakraborty BS; Hawes EM; Midha KK
    Ther Drug Monit; 1988; 10(2):205-14. PubMed ID: 3381240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.
    Cohen BM; Lipinski JF; Waternaux C
    Psychopharmacology (Berl); 1989; 97(4):481-8. PubMed ID: 2498945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and properties of haptens for the development of radioimmunoassays for thioridazine, mesoridazine, and sulforidazine.
    Chakraborty BS; Sardessai MS; Jaworski TJ; Midha KK; Hawes EM
    Pharm Res; 1987 Jun; 4(3):207-13. PubMed ID: 3509283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
    Shvartsburd A; Nwokeafor V; Smith RC
    Psychopharmacology (Berl); 1984; 82(1-2):55-61. PubMed ID: 6420831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.